Tweet
U.S. CDC Committee Recommends Against Using CSL Biotherapies Flu Vaccine in Children Under 8
Posted on Thursday Aug 5th at 10:00am
A U.S. Centers for Disease Control and Prevention advisory committee voted on Aug. 5 to withdraw a seasonal influenza vaccine manufactured by CSL Biotherapies from the U.S. market for children between the ages of 6 months and 8 years.
The company?s trivalent influenza vaccine (TIV) sold under the trade name Afluria in the United States was associated with a large increase in the risk of fevers and febrile seizures in children in Australia and New Zealand.
In April 2010, authorities in those two countries recommended that physicians suspend use of CSL?s influenza vaccines in children aged 5 years and under. In response, the company voluntarily withdrew its vaccine from markets in the southern hemisphere.
In the northern hemisphere, CSL?s influenza vaccines have been approved for use in Germany, the United Kingdom, and the United States. In June 2010, authorities in the United Kingdom recommended that physicians avoid using CSL?s influenza vaccine in children aged 5 years and under.
In making their recommendation, members of the U.S. CDC?s Advisory Committee on Immunization Practices (ACIP) noted that there should be adequate supplies of seasonal influenza vaccine even in the absence of Afluria. Other manufacturers are expected to supply 145-150 million doses of the vaccine in the United States; the largest number of doses ever used in one flu season was 114 million.
During the course of the teleconference, representatives of Sanofi-Aventis, GlaxoSmithKline, Novartis, and MedImmune all said that they had adequate supplies of vaccine, and that they were willing to increase production if necessary to compensate for the 6-12 million doses that CSL had been expected to provide.
...
Read more:
Posted on Thursday Aug 5th at 10:00am
A U.S. Centers for Disease Control and Prevention advisory committee voted on Aug. 5 to withdraw a seasonal influenza vaccine manufactured by CSL Biotherapies from the U.S. market for children between the ages of 6 months and 8 years.
The company?s trivalent influenza vaccine (TIV) sold under the trade name Afluria in the United States was associated with a large increase in the risk of fevers and febrile seizures in children in Australia and New Zealand.
In April 2010, authorities in those two countries recommended that physicians suspend use of CSL?s influenza vaccines in children aged 5 years and under. In response, the company voluntarily withdrew its vaccine from markets in the southern hemisphere.
In the northern hemisphere, CSL?s influenza vaccines have been approved for use in Germany, the United Kingdom, and the United States. In June 2010, authorities in the United Kingdom recommended that physicians avoid using CSL?s influenza vaccine in children aged 5 years and under.
In making their recommendation, members of the U.S. CDC?s Advisory Committee on Immunization Practices (ACIP) noted that there should be adequate supplies of seasonal influenza vaccine even in the absence of Afluria. Other manufacturers are expected to supply 145-150 million doses of the vaccine in the United States; the largest number of doses ever used in one flu season was 114 million.
During the course of the teleconference, representatives of Sanofi-Aventis, GlaxoSmithKline, Novartis, and MedImmune all said that they had adequate supplies of vaccine, and that they were willing to increase production if necessary to compensate for the 6-12 million doses that CSL had been expected to provide.
...
Read more:
